BioNexus Gene Lab Corp Common stock Cash Flow-to-Debt Ratio
BioNexus Gene Lab Corp Common stock cash flow-to-debt ratio. BioNexus Gene Lab Corp Common stock (BGLC) has a Cash Flow-to-Debt Ratio of -1.53x as of September 2025, meaning its operating cash flow of $-1.23 Million could theoretically repay -2% of its total liabilities ($804.97K) in one year. Check BGLC operating cash flow to net income to evaluate the quality of earnings relative to operating cash generation.
CF-to-Debt Ratio
Operating Cash Flow
Total Liabilities
Data as of
Cash Flow-to-Debt Ratio of BioNexus Gene Lab Corp Common stock (2016–2024)
Cash flow-to-debt ratio of BioNexus Gene Lab Corp Common stock from 2016 to 2024. Historical debt coverage capacity for BioNexus Gene Lab Corp Common stock across 9 annual periods. Check BGLC capex plus investments ratio to assess the company's total reinvestment commitment from operating cash flow.
BioNexus Gene Lab Corp Common stock Cash Flow-to-Debt Ratio by Year (2016–2024)
BioNexus Gene Lab Corp Common stock cash flow-to-debt ratio by year from 2016 to 2024. Year-by-year debt coverage analysis for BioNexus Gene Lab Corp Common stock. For the full cash flow conversion analysis, see cash flow conversion of BioNexus Gene Lab Corp Common stock.
| Year | CF-to-Debt Ratio | Operating CF (USD) | Total Liabilities | YoY Change |
|---|---|---|---|---|
| 2024 | -1.06x | $-2.23 Million | $2.11 Million | ▼ -4.7% |
| 2023 | -1.01x | $-1.76 Million | $1.74 Million | ▼ -485.6% |
| 2022 | 0.26x | $544.03K | $2.08 Million | ▲ +6752.7% |
| 2021 | 0.00x | $9.16K | $2.39 Million | ▼ -97.6% |
| 2020 | 0.16x | $552.68K | $3.45 Million | ▲ +108.0% |
| 2019 | -2.00x | $-217.27K | $108.87K | ▲ +5.1% |
| 2018 | -2.10x | $-274.08K | $130.31K | ▼ -793.7% |
| 2017 | 0.30x | $357.22K | $1.18 Million | ▲ +148.5% |
| 2016 | -0.62x | $-835.00 | $1.34K | — |